Loading…
JAMP-ANASTROZOLE is a brand name for Anastrozole, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: JAMP-Anastrozole (anastrozole tablets) is indicated for: • the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Approval is based on superior disease-free survival for anastrozole in comparison to tamoxifen. However, overall survival was not significantly different between…
Verbatim from this product's HC label. Tap a section to expand.
2 Recommended Dose and Dosage Adjustment JAMP-Anastrozole (Anastrozole Tablets) Page 5 of 60 JAMP-Anastrozole should be administered 1 mg orally, once a day. In the adjuvant setting, it is currently recommended that treatment be given for 5 years.
Pediatrics (< 18 years of age):
Health Canada has not authorized an indication for pediatric use for anastrozole.
Geriatrics (> 65 years of age):
No changes in dose are necessary for elderly patients (see 1 INDICATIONS).
Dose modification for Patients with Hepatic Impairment:
Although the apparent oral clearance of anastrozole was decreased in subjects with cirrhosis due to alcohol abuse, plasma anastrozole concentrations remained within the range seen across all clinical trials in subjects without liver disease.
Therefore, no changes in dose are recommended for patients with mild- to- moderate hepatic impairment, although patients should be monitored for side effects. Anastrozole has not been studied in patients with severe hepatic impairment.
3 Pharmacokinetics).
Dose modification for Patients with Renal Impairment:
No changes in dose are necessary for patients with renal impairment. 3 Pharmacokinetics). 4 Administration Patients should swallow JAMP-Anastrozole with fluids. Patients should try to take JAMP-Anastrozole at the same time each day. 5 Missed Dose A missed dose should be taken as soon as possible, as long as it is taken at least 12 hours before the next dose is due.
A missed dose should not be taken within 12 hours of the next dose.
1 Adverse Reaction Overview Adverse events have usually been mild to moderate with few withdrawals from treatment due to undesirable events. The pharmacological action of anastrozole may give rise to certain expected effects. Arthritis/arthralgia, joint pain/stiffness and hot flushes were reported very commonly (≥10%).
Common adverse reactions (≥1% - <10%) are: asthenia, bone pain, myalgia, carpal tunnel syndrome, sensory disturbances (including paraesthesia, taste loss and taste perversion), vaginal dryness, hair thinning (alopecia), rash, nausea, diarrhea, headache and increases in alkaline phosphatase, alanine aminotransferase and aspartate aminotransferase.
In the ATAC trial, ischemic cardiovascular events were reported more frequently in patients JAMP-Anastrozole (Anastrozole Tablets) Page 9 of 60 treated with anastrozole compared to those treated with tamoxifen, although the difference was not statistically significant.
A retrospective evaluation has shown that this numerical difference was associated with a sub-group of patients with pre-existing ischemic heart disease. A statistical analysis could not be performed on this subgroup evaluation. 9% vs.
7%, respectively). Events of carpal tunnel syndrome have been reported in patients receiving anastrozole treatment in clinical trials in greater numbers than those receiving treatment with tamoxifen. The majority of these events occurred in patients with identifiable risk factors for the development of the condition.
In the ATAC adjuvant trial, 83 events of carpal tunnel syndrome occurred in 78 patients in the anastrozole monotherapy arm, and 22 events occurred in 22 patients in the tamoxifen arm. Vaginal bleeding has been reported infrequently, mainly in patients during the first few weeks after changing from existing hormonal therapy to treatment with anastrozole.
Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX. General Anastrozole has not been investigated in patients with any degree of brain or leptomeningeal involvement or with pulmonary lymphangitic disseminated disease. Cardiovascular In the ATAC trial, ischemic cardiovascular events were reported more frequently in patients treated with anastrozole compared to those treated with tamoxifen, although the difference was not statistically significant.
A retrospective evaluation has shown that this numerical difference was associated with a sub-group of patients with pre-existing ischemic heart disease. A statistical analysis could not be performed on this subgroup evaluation. 9% vs.
7%, respectively). Driving and Operating Machinery JAMP-Anastrozole is unlikely to impair the ability of patients to drive and operate machinery. However, asthenia and somnolence have been reported with the use of anastrozole and caution should be observed when driving or operating machinery while such symptoms persist.
Monitoring and Laboratory Tests Anastrozole has not been observed to interfere with routine clinical laboratory test results.
Bone assessment:
Women should have their osteoporosis risk assessed and managed according to local clinical practice and guidelines.
Musculoskeletal Arthralgia/Arthritis:
The use of Aromatase Inhibitors, including anastrozole, may cause arthralgia/arthritis, which may impact on treatment compliance and quality of life. 4% of patients on the tamoxifen arm. 4% of patients on the tamoxifen arm.
Bone Mineral Density:
The use of estrogen lowering agents, including anastrozole, may cause a reduction in bone mineral density with a possible consequent increased risk of fracture. In the SABRE study, postmenopausal women with hormone receptor positive early breast cancer with existing moderate or high risk of fragility fracture, bone mineral density (BMD) loss could be inhibited by using anastrozole together with a bisphosphonate (risedronate) (see Assessment of Bone).
• Patients who are hypersensitive to JAMP-Anastrozole or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
• Pregnant or lactating women.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Anastrozole in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
If bleeding persists, further evaluation should be considered. 2 Clinical Trial Adverse Reactions Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug.
Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use. 6 months for patients receiving anastrozole 1 mg and tamoxifen 20 mg, respectively. The combination of anastrozole and tamoxifen did not demonstrate any safety benefits in comparison to tamoxifen alone after the results from the first analysis (median duration of treatment was approximately 33 months).
1% vs. 5% vs. 9%). 0%). 8) JAMP-Anastrozole (Anastrozole Tablets) Page 11 of 60 Table 2 Adverse events occurring with an incidence of at least 5%in any treatment group during or within 14 days of the end of treatment from the ATAC trial Body system and adverse event by COSTART-preferred term Number (%) of patientsa 33-month analysis […]
Myalgia:
Myalgia has been associated with both anti-estrogens and estrogen-lowering agents. 2%).
Tendon disorders:
The use of third generation aromatase inhibitors, including anastrozole, was found to be associated with tendonitis and tenosynovitis as reported in randomized controlled trials. Tendon rupture was found to be a potential risk. Tendonitis and tenosynovitis were estimated to be of uncommon occurrence, and tendon rupture of rare occurrence.
Treating physicians should monitor patients for these adverse drug reactions. 1 Pregnant Women JAMP-Anastrozole (Anastrozole Tablets) Page 8 of 60 JAMP-Anastrozole is contraindicated in pregnant women. The extent of exposure in pregnancy to anastrozole during clinical trials and postmarketing is very limited to individual cases only.
If a patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus or potential risk for loss of the pregnancy. 1 mg/kg in rats and rabbits. Studies in both rats and rabbits showed that anastrozole increased pregnancy loss.
Evidence of fetotoxicity, including delayed fetal development was observed in rats. In rabbits, anastrozole caused pregnancy failure. There was no evidence of teratogenicity in rats and rabbits. See 16 NON-CLINICAL TOXICOLOGY. 2 Breast-feeding JAMP-Anastrozole is contraindicated in lactating women.
3 Pediatrics Pediatrics (< 18 years of age): Health Canada has not authorized an indication for use in pediatric patients as safety and efficacy have not been established. 4 Geriatrics Geriatrics (> 65 years of age): Anastrozole pharmacokinetics have been investigated in postmenopausal female volunteers and patients with breast cancer.
The pharmacokinetics were similar in volunteers and in patients, and no age related effects were seen.